"BostonGene...announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This first-in-human study is being conducted at leading cancer institutions in the US and Canada to evaluate the safety and preliminary efficacy of LCB84, both as a single-agent therapy and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody)....BostonGene will serve as the study’s central laboratory and analytic partner for exploratory biomarkers, performing in-depth, multi-omic profiling of patients’ tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies on the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample."

6 months ago

Licensing / partnership

LCB84

7ms

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=300, Recruiting, LegoChem Biosciences, Inc | Not yet recruiting --> Recruiting

7 months ago

Enrollment open • Combination therapy • Metastases

LCB84

10ms

Phase 1/2 Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=300, Not yet recruiting, LegoChem Biosciences, Inc

10 months ago

New P1/2 trial • Combination therapy • Metastases

LCB84